A Case Study on Fractional Expertise: Pharmefex and Early CMC Strategy
ISSUE — 12 · OCTOBER 2026
Download PDF here:
Prepared by Henning Mann, PhD | Founder & Principal, HM.BioConsulting
In Collaboration with Kaela Siahpush, Pharmefex
October 2026 | Version 1.0
INTRODUCTION
Promising scientific innovations ranging from novel solutions in biotech, from consumables to bio- or medtech hardware to an actual innovative new drug can move from discovery toward pre- or clinical applications and assessments long before a young biotechnology company has built every function needed to support it. Specialized judgement and expertise is needed early on, whether that is to define market and positioning, proof-of-concept work, commercial and competitive landscape, go-to-market strategies and building a robust sales infrastructure and partnerships. In drug manufacturing, it is efforts in process development, analytical characterization, manufacturing oversight, quality systems, regulatory strategy, and eventually commercial readiness which require specialized judgment. Yet, these needs rarely arrive at the same time or justify the same level of permanent staffing. This tension has contributed significantly to make fractional and project-based expertise an increasingly practical part of how emerging life-science companies operate.
At HM.BioConsulting, we see the value of this approach across business development, commercialization, scientific strategy, and operational execution every day and with every one of our partners. Our experienced specialists can work alongside an existing team, take responsibility for a defined scope, and scale their involvement as milestones change. The fractional model works so well because it brings instant expertise, continuity and accountability without extensive onboarding or training. Additionally, it helps preserve resources for the experiments, manufacturing campaigns, and regulatory work that determine a program’s next step.
Chemistry, Manufacturing, and Controls (CMC) is a great example to illustrate why this matters.
Manufacturing decisions made early affect comparability, analytical strategy, technology transfer, inspection readiness, and the ability to manage changes later in development. For a small sponsor coordinating several external partners, these decisions need an experienced owner even when a full-time CMC department is not yet practical or even possible.
For this HM.BioConsulting Spotlight, we invited Pharmefex, one of our valued clients and a specialist consultancy supporting biologics and advanced therapies, to share its perspective. Founded in 2014, Pharmefex provides CMC development, quality and regulatory, manufacturing, risk management, and outsourcing support. Our conversation explores where programs encounter avoidable difficulty, why CMC should be considered throughout development, and how access to experienced outside expertise can help sponsors prepare before problems become urgent.
01 Pharmefex on (Fractional) CMC
HMBC: CMC is often described as “the backbone” of drug development. Why does it still catch teams off guard?
Pharmefex:
A drug rarely fails because CMC is ignored. It likely fails because CMC is treated as something to finalize later rather than the structure to build from. Development timelines often advance faster than the chemistry understanding, quality assurance and controls, which maintain consistency and safety, thus the success of a drug. That gap only becomes visible when submissions are imminent, or after submission when the FDA returns with information requests or refusal to file. At that point, options to fix a problem narrow quickly.
The distinction between a manageable development risk and a costly late-stage problem often comes down to when it is recognized. Fractional specialists can be particularly useful here: they bring experience from other programs and can challenge assumptions before a small team commits scarce time and resources.
HMBC: What are you seeing most often as the root cause of CMC-driven delays today?
Pharmefex:
The most common issues are incomplete control strategies, underdeveloped comparability plans, and manufacturing systems that are not inspection-ready. Companies with low overhead often attempt to reduce cost by relying on internal development then low cost CDMO without proper alignment or management, which can result in these issues later down the road. These issues are usually not surprises but instead are known risks that were not addressed early enough. When CMC documentation fails to demonstrate adequate product quality or manufacturing control due to lack of or incomplete validation, companies will experience delays which then will consume more time and budget than originally planned.
These challenges also highlight why hiring decisions should follow the program’s needs. A company may need deep analytical or manufacturing expertise for a specific transition, followed by lighter ongoing oversight. The next question is how the expectations facing those teams have evolved.
HMBC: Has the regulatory bar for CMC changed in recent years?
Pharmefex:
The science has not changed dramatically, but regulatory expectations around clarity, traceability, and lifecycle thinking have become much sharper. Regulators increasingly expect sponsors to demonstrate not just that a process works today, but that it will remain controlled as the program scales and evolves. This requires more forward thinking, and expertise on CMC strategy than many early-stage biopharma companies have available. It helps to employ experts who can bridge that knowledge gap.
For emerging modalities, early process knowledge and a realistic development plan are especially important. Bringing in specialized experience at the right stage can help teams prioritize what must be established now and what can appropriately mature later.
HMBC: Gene and cell therapies seem especially exposed to CMC challenges. Why?
Pharmefex:
Advanced therapies combine biological complexity with limited clinical material and evolving processes. Potency, raw material variability, and comparability are inherently harder to define, making control strategy, manufacturing processes, quality control and consistency more difficult to target early on. Additionally, the C> space is newer, and each drug’s timeline is ever shrinking to be the first to file, which often results in less time taken on CMC, to cut corners. All of this makes early CMC discipline critically important.
Outsourcing manufacturing may reduce the need for internal facilities, but it does not remove the need for sponsor-side technical leadership. Choosing and managing a CDMO requires more than a contract: it requires aligned responsibilities, sound technical decisions, and sustained oversight.
HMBC: Where do companies underestimate the impact of third-party manufacturing?
Pharmefex:
We see companies mismanage contracts with third parties and underestimate the oversight needed for CDMO or CMO partnership. Sponsors often assume CDMOs will “handle compliance”, or have sufficient regulatory controls, strategy and documentation practices. In reality, accountability always stays with the sponsor, making regulatory and documentation alignment even more necessary, while using an outside manufacturing organization. Weak oversight, weak management and low quality auditing of partners is one of the fastest ways for CMC issues to cascade into regulatory delays.
When manufacturing, analytical, quality, and regulatory workstreams are not coordinated, problems often surface near a filing or other critical milestone. One advantage of an embedded fractional CMC partner is the ability to maintain that cross-functional view without waiting for an emergency.
HMBC: How do late-stage “CMC fire drills” typically start?
Pharmefex:
Fire drills are not ideal or planned necessarily. They usually begin when teams attempt to align analytics, validation, stability, and documentation simultaneously under submission pressure. When CMC strategy and Quality by Design isn’t incorporated early on, organizing can be more complex than necessary, causing need for rapid intervention, auditing, or expensive assessments to resolve process failures, analytical variances, or missing data before submission. The “fire drill” is necessitated by poor CMC oversight early on. And compression of timeline with disorganization of strategy creates stress, errors, and reactive decision-making, which regulators can see immediately.
A structured development approach can help teams make deliberate choices while budgets remain constrained. Quality by Design offers a useful framework for linking product understanding, process knowledge, risk assessment, and controls as development progresses.
HMBC: There is a focused attention on Quality by Design. Why is QbD in the spotlight and what does it do?
Pharmefex:
QbD creates a framework to establish your quality, compliance and development foundation to ensure manufacturing and data produced is aligned early on. This design links critical quality attributes to scalability and risk management, thinking of the future and filing, prior to “necessity”. In constrained funding environments, that connection matters, although many developers opt to design later to save cost early on, thinking of a long term CMC plan typically costs less money long term.
The same discipline matters beyond the regulatory submission. Investors and prospective partners often need to understand whether a company has a credible path from promising science to reproducible manufacturing. An experienced external CMC perspective can help leadership identify and explain the principal technical risks.
HMBC: How are investors viewing CMC maturity today?
Pharmefex:
CMC maturity has become a proxy for execution risk. Investors increasingly ask whether a program can scale, transfer, and sustain quality, potency and robust results, to ensure their investment is well worth it. Investors are employing CMC experts to evaluate companies processes and CMC to make a decision on capital funding or acquisition. Well-articulated CMC strategies reduce uncertainty and signal operational discipline, and robust systems.
Digital tools add another dimension to this picture. As AI and advanced analytics enter manufacturing and quality workflows, teams need to evaluate their intended use, the reliability of their data, and the controls needed to maintain confidence in their outputs. New technology does not eliminate the need for sound CMC judgment.
HMBC: Digitalization and AI are entering CMC discussions. What should sponsors keep in mind?
Pharmefex:
As AI and digitization are implemented more heavily, ensuring it is kept on track is necessary. Use of AI Technology is acceptable and encouraged when its role is clearly defined, and used for evaluation, not data generation. Models must be developed for a specific context of use, supported by fit-for-purpose data, and maintained over time. The technology itself is rarely the issue. Governance of the technology is key to its successful use.
Being prepared for the unexpected is essential for success. Programs will still encounter unexpected results, supplier constraints, and changing requirements. It matters whether the team has a workable process for recognizing risks, deciding what to do, and keeping the technical and regulatory story coherent.
HMBC: What distinguishes programs that move smoothly through IND and BLA review?
Pharmefex:
Programs that have “smoother” filing typically engage in CMC early on, they treat CMC as a continuous system rather than a milestone or something to implement later in clinical trials. Gaps are identified early, assumptions are stress-tested, and regulatory interactions are prepared well in advance. There are fewer surprises because fewer things are left implicit, and more are forethought.
This leads to a question that matters to both biotech leaders and consultants. When should a company bring in CMC expertise? From our experience, the fractional model is most valuable when it is integrated early enough to shape decisions, while remaining flexible enough to match the actual workload and stage of development.
HMBC: What is the biggest misconception about CMC consulting?
Pharmefex:
That it is only about fixing problems, or should only be used later - post IND. In reality, the most valuable work happens early and pre-IND, even in discovery phase, prior to IND upstream where we provide support; for example, in shaping strategy, aligning teams, and preventing issues from materializing in the first place. Then helping the regulatory and filing strategy, in addition to planning for later stages. Many companies do not have people with development, regulatory, and quality skills, CMC provides it all.
For founders and leadership teams, the practical issue is not whether every capability should sit inside the company. Rather, we find that it is whether the right expertise is engaged, with clear responsibilities, at the moments when its decisions will have lasting consequences.
HMBC: What would you want emerging biotech leaders to internalize about CMC?
Pharmefex:
How a drug is made is inseparable from whether it succeeds. CMC is not a regulatory hurdle to clear at the end of the race. It is part of the product’s scientific identity from the beginning. Its the foundation of your quality, control and manufacturing. Your development, clinical and life cycle management all involve CMC, and engaging people who know what they are doing is just as important as having people who research and work in manufacturing.
02 Outlook and Conclusions
The discussion with Pharmefex illustrates a broader shift in how emerging biotechnology companies can build capability. Rather than carrying every specialized function as permanent overhead from the outset, sponsors can combine a focused internal team with experienced fractional partners who provide strategic continuity, hands-on support, and independent perspective. That approach still requires clear ownership, effective communication, and thoughtful integration with internal teams and external manufacturers.
For HM.BioConsulting, this is the case for thoughtful fractional consulting: match the depth and timing of expertise to the program, make responsibilities explicit, and keep experienced people close enough to influence decisions before options narrow. Pharmefex demonstrates how that principle applies in CMC, where the consequences of early choices may not become visible until much later. We are pleased to spotlight their perspective and the work they do to help biotechnology companies plan, develop, and manufacture with greater confidence.
Explore Pharmefex at www.pharmefex.com and HM.BioConsulting at www.hmbioconsulting.com.
© 2026 HM.BioConsulting. All rights reserved. This document is prepared for informational purposes only and does not constitute regulatory, legal, or financial advice. All links and sources verified at time of publication.
Comments